ClinicalTrials.gg
Not yet recruitingNCT07836127Updated Sep 23, 2026

Human Albumin Combined With Plasma Exchange for Frailty Intervention

An interventional study of Plasma Exchange and 5% human albumin in Frailty and Plasma Exchange, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies in Frailty with a site in China — 25 open to participants now, 27 under way, none of them phase 3. Frailty · China.

Planned enrollment
28th of 31
34 · median 164
Started
2026
with 4 others
No phase
25 of 64
11 open now
Primary completion
2028-05
later than 21 of 26 live
Registered
60th of 64
by date

Among the 64 studies in Frailty with a site in China, this one is the 28th largest by planned enrollment of the 31 interventional ones that give a count, is one of 5 that started in 2026, is one of 25 with no phase, reaches primary completion later than 21 of the 26 other live ones, and was the 60th registered.

Frailty

1,286 studies on the registry are indexed under Frailty; 454 are open to participants now.

Browse Frailty studies →

Open to participants now

25 of the 64 studies in Frailty with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 301 Frailty studies recruiting now, 236 (78%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 67 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Frailty with a site in China, or all of them as a file.
02

Study summary

Background Frailty is an age-related syndrome characterized by reduced physiological reserve, decreased stress tolerance and multisystem functional decline in the elderly, which markedly increases the risks of falls, hospitalization, functional impairment and all-cause mortality. Chronic low-grade inflammation, immune senescence, oxidative stress and abnormal protein modification are key mechanisms underlying the development and progression of frailty. Current mainstream interventions including nutritional support and physical exercise yield limited efficacy for moderate to severe frailty, and targeted therapies against biological aging mechanisms are still lacking.Objective To evaluate the efficacy and safety of plasma exchange combined with human albumin (ALB), with or without intravenous immunoglobulin (IVIg), in the treatment of frailty, and to preliminarily explore the potential mechanisms of the combined therapy.Methods This is a prospective, randomized, exploratory clinical trial. A total of 34 participants with a FRAIL scale score ≥ 1 will be enrolled and randomly assigned at a 1:1 ratio into two groups, with 17 cases in each group: the plasma exchange plus ALB group and the plasma exchange plus ALB plus IVIg group. The study consists of a screening phase, a 5-month treatment phase with six intervention sessions, and follow-up visits at 1, 3 and 6 months after the final treatment. Frailty status, physical function, laboratory parameters, inflammatory levels and albumin modification will be dynamically assessed throughout the trial, and adverse events will be recorded.Results The trial has not yet been initiated. It is expected that the within-group and between-group comparisons will clarify the therapeutic effects and long-term stability of the two regimens, as well as their safety profiles. Changes in biomarkers will help illustrate the potential molecular mechanisms of plasma purification combined with functional protein supplementation for frailty.Conclusion Plasma exchange combined with ALB (with or without IVIg) can exert multi-target intervention on frailty by eliminating aging-related toxic factors and restoring plasma and immune homeostasis. The findings of this study will provide preliminary clinical evidence and theoretical basis for novel biological therapeutic strategies for frailty.

Read the detailed description

Frailty is a common age-related clinical syndrome characterized by progressive decline in physiological reserve, reduced stress tolerance, and multisystem functional impairment in older adults. It significantly increases the risk of adverse outcomes including falls, hospitalizations, functional dependence, and all-cause mortality. Chronic low-grade inflammation, immune senescence, oxidative stress, and abnormal protein modification are considered key biological mechanisms driving the onset and progression of frailty. Current mainstream interventions, such as nutritional support and physical exercise, have shown only limited efficacy in moderate to severe frailty, and targeted biological therapies for frailty remain lacking. This study aims to evaluate the efficacy and safety of plasma exchange combined with human albumin (ALB), with or without adjunctive intravenous immunoglobulin (IVIg), in the treatment of frailty, and to preliminarily explore the potential mechanisms underlying the combined therapy.

This is a prospective, randomized, exploratory clinical trial. A total of 34 participants with a FRAIL scale score of ≥ 1 will be enrolled and randomly assigned at a 1:1 ratio into two groups (17 participants in each group): the plasma exchange plus human albumin group (ALB group) and the plasma exchange plus human albumin plus intravenous immunoglobulin group (ALB + IVIg group). The study is divided into three phases: a screening phase, a treatment phase, and a follow-up phase.

The screening phase will be conducted within 7 days prior to the first treatment. Eligible subjects will sign an informed consent form and complete a comprehensive baseline assessment, including frailty status evaluation, physical function testing, routine laboratory and imaging examinations, frailty-related biomarker detection, albumin (ALB) modification profiling, and inflammatory marker testing to confirm eligibility.

The treatment phase will last for 5 months, consisting of a total of 6 treatment sessions administered monthly. Systemic assessments will be performed at each visit, including frailty status evaluation, physical function testing, routine pre-treatment examinations, frailty-related biomarker detection, ALB modification profiling, and inflammatory marker testing, to monitor treatment response and safety. Blood samples for complete blood count and coagulation function will be collected within 1 hour after the first plasma exchange session. All participants will receive plasma exchange with 5% human albumin solution as the replacement fluid, according to the study protocol. Subjects in the ALB + IVIg group will additionally receive intravenous immunoglobulin (IVIg) immediately after each plasma exchange session. Adverse events will be recorded throughout the study.

Follow-up visits will be conducted at 1, 3, and 6 months after the final treatment session. All assessments and laboratory tests will be repeated to evaluate the long-term efficacy, safety, and sustained effects of the interventions.

This trial has not yet been initiated. It is expected that within-group and between-group comparisons will clarify the therapeutic effects and long-term stability of the two regimens, as well as their safety profiles. Changes in frailty-related biomarkers, inflammatory markers, and albumin modification patterns will help to illustrate the potential molecular mechanisms of plasma exchange combined with functional protein supplementation for frailty. It is hypothesized that plasma exchange combined with ALB (with or without IVIg) may exert multi-targeted intervention on frailty by eliminating aging-related toxic factors and restoring plasma and immune homeostasis. The findings of this study will provide preliminary clinical evidence and a theoretical basis for novel biological therapeutic strategies for frailty.

03

Conditions studied

  • Frailty
  • Plasma Exchange

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years.
  2. Clear consciousness and ability to communicate.
  3. Sufficient cognitive function and educational level to complete all study-related assessments.
  4. A score of ≥ 1 on the FRAIL scale.
  5. Voluntary written .

Exclusion criteria

Exclusion Criteria:

  1. Known allergy or to albumin (ALB) or intravenous immunoglobulin (IVIg).
  2. Currently receiving albumin (ALB) and/or intravenous immunoglobulin (IVIg) infusion for other reasons.
  3. Severe cardiac, hepatic, or renal insufficiency.
  4. Active infection or acute exacerbation of chronic infection.
  5. Current use of direct oral anticoagulants (DOACs).
  6. History of bleeding disorders or coagulation dysfunction.
  7. Concomitant or expected survival of less than 6 months.
  8. Severe visual, auditory, or motor function impairment.
  9. Refusal to sign the form.
  10. Other conditions that, in the opinion of the investigator, make the participant unsuitable for the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    Plasma Exchange + Human Albumin Group

    All subjects receive standard background therapy. Subjects receive monthly plasma exchange for 6 cycles with 5% human albumin as replacement fluid, no IVIg administration.

    Procedure: Plasma Exchange · Biological: 5% human albumin

  • Experimental
    Experimental: Plasma Exchange + Human Albumin + IVIg Group

    All subjects receive standard background therapy. Subjects receive monthly plasma exchange for 6 cycles with 5% human albumin replacement fluid, plus IVIg 2.5 g after each exchange session.

    Procedure: Plasma Exchange · Biological: 5% human albumin · Biological: Intravenous immunoglobulin (IVIG)

Interventions

  • ProcedurePlasma Exchange

    Plasma exchange procedure, target exchange volume 50±5 mL/kg per session, flow rate 40-60 mL/min, administered once monthly for 6 cycles.

  • Equal-volume 5% human albumin solution used as replacement fluid during plasma exchange.

  • IVIg administered at a fixed dose of 2.5 g per subject, infused immediately after each plasma exchange session.

06

What researchers measure

Primary outcomes

  1. Efficacy rate of frailty intervention at 1 month after the last treatment

    Calculation formula: \[(Baseline score - Follow-up score at 1 month after the last treatment) / Baseline score\] × 100%. This rate represents the degree of improvement in patients' frailty status following intervention.

    Time frame: 1 month after the last treatment

Secondary outcomes

  1. Efficacy rate of frailty intervention assessed by FRAIL Scale

    The efficacy rate of frailty intervention calculated based on the FRAIL Scale (Fatigue, Resistance, Ambulation, Illnesses, Loss of weight). The scale ranges from 0 (no frailty) to 5 (severe frailty); higher scores indicate worse frailty status. Efficacy rate = (Baseline score - Score at follow-up) / Baseline score × 100%.

    Time frame: Baseline, 4 week, 8 week, 12 week, 16 week, 20 week, 24 week, 28 week, and 32 week after enrollment

  2. Strand specificity of frailty-related cfDNA and therapeutic response to plasma exchange

    Assess strand specificity of frailty-related circulating cell-free DNA and evaluate its predictive value for plasma exchange treatment response.

    Time frame: Baseline, 1 month and 6 months after the last treatment

  3. Clonal hematopoiesis gene mutation dynamics and correlation with frailty

    Observe clonal hematopoiesis-associated gene mutation and clonal evolution at baseline, 1 month and 6 months post last treatment; explore the correlation between clonal hematopoiesis features and frailty status.

    Time frame: Baseline, 4 week,24 week, 28 week, and 32 week after enrollment

  4. BCR clonotype characteristics

    Analysis of BCR clonotype derived from identical BCR high-throughput sequencing assay. Assessments are performed at baseline, 1 month and 6 months after the last treatment.

    Time frame: Baseline, 1 month and 6 months after the last treatment

  5. BCR V/J gene usage bias

    Analysis of BCR V/J gene usage bias derived from identical BCR high-throughput sequencing assay. Assessments are performed at baseline, 1 month and 6 months after the last treatment.

    Time frame: Baseline, 1 month and 6 months after the last treatment

  6. BCR diversity index

    Analysis of BCR diversity index derived from identical BCR high-throughput sequencing assay. Assessments are performed at baseline, 1 month and 6 months after the last treatment.

    Time frame: Baseline, 1 month and 6 months after the last treatment

  7. Frequency of senescence-associated antigen-specific B cell clones

    Analysis of senescence-associated antigen-specific B cell clones derived from identical BCR high-throughput sequencing assay. Assessments are performed at baseline, 1 month and 6 months after the last treatment.

    Time frame: Baseline, 1 month and 6 months after the last treatment

  8. TCR clonotype characteristics

    Analysis of TCR clonotype derived from a single unified TCR high-throughput sequencing assay. Assessments are performed at baseline, 1 month and 6 months after the last treatment.

    Time frame: Baseline, 1 month and 6 months after the last treatment

  9. TCR diversity index

    Analysis of TCR diversity index derived from a single unified TCR high-throughput sequencing assay. Assessments are performed at baseline, 1 month and 6 months after the last treatment.

    Time frame: Baseline, 1 month and 6 months after the last treatment

  10. TCR V/J gene usage bias

    Analysis of TCR V/J gene usage bias derived from a single unified TCR high-throughput sequencing assay. Assessments are performed at baseline, 1 month and 6 months after the last treatment.

    Time frame: Baseline, 1 month and 6 months after the last treatment

  11. Frequency of senescence-associated antigen-specific T cell clones

    Analysis of senescence-associated antigen-specific T cell clones derived from a single unified TCR high-throughput sequencing assay. Assessments are performed at baseline, 1 month and 6 months after the last treatment.

    Time frame: Baseline, 1 month and 6 months after the last treatment

  12. Between-group differences in frailty scale score: ALB group vs ALB+IVIg group

    Compare the changes of frailty scale score between albumin monotherapy group and albumin combined with IVIg group.

    Time frame: Baseline, 4 week, 8 week, 12 week, 16 week, 20 week, 24 week, 28 week, and 32 week after enrollment

  13. Baseline changes of serum ALB modification at 1 month after last treatment

    Evaluate the alterations of serum albumin subtypes including oxidation, glycation, nitration, sulfenylation, cysteinylation, cysteinylation combined with glycation versus baseline.

    Time frame: 1 month after the last treatment

  14. Changes from baseline in senescence-related indicators at 1 month after last treatment

    Detect plasma proteome and glycoproteome related to senescence, including SASP, serum inflammatory factors and epigenetic senescence clock, and analyze their changes compared with baseline.

    Time frame: 1 month after the last treatment

  15. Changes from baseline in Tilburg Frailty Indicator (TFI) scores

    To evaluate the changes of Tilburg Frailty Indicator (TFI) score compared with baseline at each follow-up time point.

    Time frame: Baseline, 4 week, 8 week, 12 week, 16 week, 20 week, 24 week, 28 week, and 32 week after enrollment

  16. Changes from baseline in Fried Frailty Phenotype Scale scores

    To evaluate the change of Fried Frailty Phenotype Scale score compared with baseline. This is one single outcome indicator (scale score) assessed repeatedly at multiple planned follow-up time points, not multiple distinct outcome measures.This represents one continuous outcome (Frailty Phenotype score) assessed longitudinally at multiple prespecified time points.

    Time frame: Baseline, 4 week, 8 week, 12 week, 16 week, 20 week, 24 week, 28 week, and 32 week after enrollment

  17. Changes from baseline in physical and mental health questionnaire scores

    Assess changes from baseline in EQ-5D, PROMIS-29, Generalized Anxiety Disorder (GAD) scale, Patient Health Questionnaire (PHQ), Pittsburgh Sleep Quality Index (PSQI).

    Time frame: Baseline, 4 week, 8 week, 12 week, 16 week, 20 week, 24 week, 28 week, and 32 week after enrollment

  18. Short Physical Performance Battery (SPPB) score

    To evaluate patients' physical function using the Short Physical Performance Battery (SPPB). This single continuous scale outcome will be repeatedly assessed at multiple scheduled follow-up time points.

    Time frame: Baseline, 4 week, 8 week, 12 week, 16 week, 20 week, 24 week, 28 week, and 32 week after enrollment

  19. Changes in gene mutation frequency and its correlation with immune cell subsets

    Analyze the shift of gene mutation frequency before and after treatment, and explore the correlation between mutation frequency and immune cell profiles.

    Time frame: Baseline, 1 month and 6 months after the last treatment

  20. Changes from baseline in CRP

    Detect serum CRP, and calculate their changes compared with baseline at predefined visits.

    Time frame: Baseline, 4 week, 24 week, 28 week, and 32 week after enrollment

  21. Changes from baseline in ESR levels

    Detect serum erythrocyte sedimentation rate (ESR) , and calculate their changes compared with baseline at predefined visits.

    Time frame: Baseline, 4 week, 24 week, 28 week, and 32 week after enrollment

  22. Changes from baseline in ferritin levels

    To assess changes in serum ferritin concentration relative to baseline.

    Time frame: Baseline, 4 week, 24 week, 28 week, and 32 week after enrollment

  23. Incidence of adverse events during treatment

    The incidence rate of all adverse events occurring during the treatment period will be calculated. Focused adverse events include catheter-related infections, hypersensitivity reactions, thrombosis, and other related adverse events.

    Time frame: From initiation of the first treatment through 6-month after completion of all study treatments, assessed up to 12 months

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for May 2028, 19 months later.

Of 514 non-industry interventional studies with no phase under Frailty, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 39. This study's planned 19 months is below that.

Counting every sponsor, half of 518 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2026
First posted
Sep 23, 2026
StartEst.
Sep 24, 2026
Primary completionEst.
May 14, 2028
CompletionEst.
Nov 14, 2028
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07836127
Responsible party
Sponsor
First posted
Sep 23, 2026
Start date
Sep 24, 2026 (estimated)
Primary completion
May 14, 2028 (estimated)
Completion
Nov 14, 2028 (estimated)
Last update
Sep 23, 2026

Study contacts

Ying Wang
Contact
wangying@ihcams.ac.cn
022-23608316

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albumins human

Start the discussion